PDCD1LG2

Transcenta Announces Updated Clinical Data from Phase I Study of pH-Dependent PD-L1 Antibody MSB2311 to Be Presented at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, May 14, 2021
Clusters of differentiation, Branches of biology, Immunology, Medical specialties, Programmed cell death protein 1, PD-L1, Tumor microenvironment, L1, E-selectin, Cancer immunotherapy, PDCD1LG2

MSB2311 blocks the interaction between PD-L1 and PD-1, which reactivates the suppressed or exhausted anti-tumor effector T cell function in the tumor microenvironment.

Key Points: 
  • MSB2311 blocks the interaction between PD-L1 and PD-1, which reactivates the suppressed or exhausted anti-tumor effector T cell function in the tumor microenvironment.
  • In addition, the binding of MSB2311 to PD-L1 results in internalization of MSB2311 and MSB2311 can dissociate from bound PD-L1 in endosome with pH level lower than 5.5.
  • Results from preclinical studies demonstrate that MSB2311 can inhibit tumor growth of PD-L1 expressing tumor cells in syngeneic mouse-model.
  • Transcenta is developing a panel of nine antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

Agenus to Present at the 2021 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 28, 2021
Medical specialties, Clusters of differentiation, Clinical medicine, Medicine, Immune system, Agenus, Cancer treatments, Immunology, Programmed cell death protein 1, PD-L1, Cancer immunotherapy, PDCD1LG2

b"LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will give two presentations at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting poster sessions.

Key Points: 
  • b"LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will give two presentations at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting poster sessions.
  • The 2021 ASCO Annual Meeting will take place virtually on June 4 \xe2\x80\x93 8, 2021.\nBalstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2.
  • PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.
  • Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release.